9AZU | pdb_00009azu

Crystal structure of PDC-3 beta-lactamase in complex with taniborbactam


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.73 Å
  • R-Value Free: 
    0.205 (Depositor), 0.216 (DCC) 
  • R-Value Work: 
    0.166 (Depositor), 0.178 (DCC) 
  • R-Value Observed: 
    0.168 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9AZU

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history

Literature

Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion Pseudomonas -derived cephalosporinase variant PDC-88.

Mack, A.R.Kumar, V.Bethel, C.R.Taracila, M.A.Miller, B.A.Uehara, T.Six, D.A.Papp-Wallace, K.M.van den Akker, F.Bonomo, R.A.

(2025) Antimicrob Agents Chemother 69: e0007825-e0007825

  • DOI: https://doi.org/10.1128/aac.00078-25
  • Primary Citation Related Structures: 
    9AZU, 9AZW, 9AZY

  • PubMed Abstract: 

    Pseudomonas aeruginosa is a major gram-negative pathogen responsible for a variety of infections and possessing an array of both intrinsic and acquired resistance mechanisms, including β-lactamases, like the chromosomal Pseudomonas -derived cephalosporinase (PDC). β-Lactams are the most widely prescribed class of antibiotics in the United States, and antipseudomonal cephalosporins (including cefepime) are important therapies (alone or combined with β-lactamase inhibitors) for P. aeruginosa infections. Taniborbactam is a novel, bicyclic boronate β-lactamase inhibitor with activity against all β-lactamase classes and is being developed in combination with cefepime. PDC-88 is an R2-loop deletion variant conferring resistance to cefepime and ceftazidime and elevating ceftolozane/tazobactam minimum inhibitory concentration (MIC). Herein, we elucidated PDC-88 resistance mechanisms and compared inhibition by taniborbactam and avibactam. In an isogenic background, PDC-88 increased cefepime MICs by 16-fold compared to PDC-3. In vitro , compared to PDC-3, PDC-88 had 8.3-fold higher catalytic efficiency for cefepime achieved by decreasing K M 12.8-fold and decreasing k cat 1.6-fold. This is supported by our crystallographic observation that the PDC-88 deletion enlarged the active site in the vicinity of the R2-loop, likely better accommodating cefepime. Taniborbactam and avibactam restored cefepime activity by inhibiting PDC-88. Compared to avibactam, taniborbactam had 4.1- and 9-fold lower K i app values for PDC-3 and PDC-88, respectively, with higher k on ( k 2 / K ) and similar k off for both enzymes. Structurally, taniborbactam positioned very similarly in the PDC-3 and PDC-88 active sites, interacting with many nearby residues. Based upon these data, cefepime-taniborbactam may represent an important alternative to ceftazidime-avibactam and ceftolozane-tazobactam for P. aeruginosa infections.


  • Organizational Affiliation
    • Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA.

Macromolecule Content 

  • Total Structure Weight: 43.81 kDa 
  • Atom Count: 3,129 
  • Modeled Residue Count: 359 
  • Deposited Residue Count: 397 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Beta-lactamase397Pseudomonas aeruginosaMutation(s): 0 
Gene Names: ampC
EC: 3.5.2.6
UniProt
Find proteins for P24735 (Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1))
Explore P24735 
Go to UniProtKB:  P24735
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP24735
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
KJK
(Subject of Investigation/LOI)

Query on KJK



Download:Ideal Coordinates CCD File
B [auth A](3~{R})-3-[2-[4-(2-azanylethylamino)cyclohexyl]ethanoylamino]-2-oxidanyl-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
C19 H28 B N3 O5
PFZUWUXKQPRWAL-NOLJZWGESA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.73 Å
  • R-Value Free:  0.205 (Depositor), 0.216 (DCC) 
  • R-Value Work:  0.166 (Depositor), 0.178 (DCC) 
  • R-Value Observed: 0.168 (Depositor) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 44.767α = 90
b = 70.573β = 90
c = 105.192γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
Aimlessdata scaling
REFMACrefinement
PDB_EXTRACTdata extraction
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
VenatoRx PharmaceuticalsUnited States--

Revision History  (Full details and data files)

  • Version 1.0: 2025-03-19
    Type: Initial release
  • Version 1.1: 2025-06-25
    Changes: Database references
  • Version 1.2: 2025-07-09
    Changes: Database references